期刊文献+

2011至2013年仁济医院神经外科病房分离的鲍曼不动杆菌的耐药性变迁与同源性分析 被引量:2

Investigation on drug resistance variation and homology of Acinetobacter baumannii isolated from patients in neurosurgery department at Renji Hospital from 2011 to 2013
下载PDF
导出
摘要 目的了解仁济医院神经外科病房分离的鲍曼不动杆菌的耐药性变迁和分子流行特征,分析菌株基因同源性,为临床治疗和医院感染控制提供依据。方法收集2011年7月至2013年6月仁济医院神经外科病房分离的鲍曼不动杆菌共87株,采用琼脂稀释法检测菌株对临床12种抗菌药物的最低抑菌浓度(MIC)。采用多位点序列分型(MLST)技术鉴定基因型别并进一步分析菌株流行特征。结果仁济医院神经外科病房分离的鲍曼不动杆菌对头孢菌素类、喹诺酮类、氨基糖苷类和碳青霉烯类抗菌药物普遍耐药,且耐药率有逐年上升趋势。87株鲍曼不动杆菌分为6个ST型,分别是ST-208(45株)、ST-191(15株)、ST-540(8株)、ST-195(2株)、ST-381(2株)和ST-368(1株),其中ST-208型是主要流行型别。除ST-381外,其余5种型别均属于CC92克隆群,具有基因同源性。结论仁济医院神经外科病房分离的鲍曼不动杆菌耐药率高且有逐年上升趋势,同时存在耐碳青霉烯类鲍曼不动杆菌的播散流行,需加强医院感染控制,防止耐药株传播。 Objective To investigate the drug resistance variation and molecular epidemiology of Acinetobacter baumannii isolated from patients in neurosurgery department at Renji Hospital and analyze the homology,in order to provide the reference for clinical treatment and nosocomial infection control. Methods A total of 87 clinical isolates of Acinetobacter baumannii were collected from July 2011 to June 3013 in neurosurgery department of Renji Hospital. The minimal inhibitory concentrations( MIC) of 12 antimicrobial agents against 87 Acinetobacter baumannii isolates were determined by agar dilution method. The genotype was identified by multilocus sequence typing technique,and the epidemiology characteristic was analyzed further. Results The 87 Acinetobacter baumannii isolates were commonly resistant to cephalosporin,fluoroquinolone,aminoglycoside and carbopenem,and the drug resistance rates increased year by year. A total of 6 genotypes were identified among 87 Acinetobacter baumannii isolates: ST-208( 45 isolates),ST-191( 15 isolates),ST-540( 8 isolates),ST-195( 2 isolates),ST-381( 2 isolates) and ST-368( 1 isolate). ST-208 was the main epidemiology type. The ST types had the homologous relevance belonging to CC92 except for ST-381.Conclusions The drug resistance rate of Acinetobacter baumannii to antimicrobial agents increases year by year,and there is dissemination characteristic,which should be paid more attention. Infection monitoring should be enhanced to reduce the spread of drug-resistant bacteria.
出处 《检验医学》 CAS 2014年第9期909-912,共4页 Laboratory Medicine
基金 上海市自然科学基金资助项目(11ZR1421200)
关键词 鲍曼不动杆菌 最低抑菌浓度 多位点序列分型 Acinetobacter baumannii Minimal inhibitory concentration Multilocus sequence typing
  • 相关文献

参考文献11

  • 1FuY,ZhouJ,ZhouH,etal.WidedisseminationofOXA-23-producing carbapenem-resistantAcinetobacterbaumanniiclonalcomplex22inmultiplecitiesofChina[J].JAntimicrobChemother,2010,65(4):644-650.
  • 2ClinicalandLaboratoryStandardsInstitute.Performancestandards for antimicrobialsusceptibility testing:twenty-firstinformationalsupplement[S]. M100-S22,CLSI,2012.
  • 3苏运钦,叶聪秀,车玉传,刘菊珍,邹海珠,余广超.多位点序列分型技术在鲍曼不动杆菌同源性分析中的应用[J].中国抗生素杂志,2013,38(5):360-362. 被引量:15
  • 4PelegAY,SeifertH,PatersonDL,etal.Acinetobacterbaumannii:emergenceofasuccessfulpathogen[J].ClinMicrobiolRev,2008,21(3):538-582.
  • 5朱德妹,杨洋,蒋晓飞,王传清,王爱敏,刘瑛,陈峰,倪语星,孙景勇,应春妹,汪雅萍,张泓,孔菁,蒋燕群,汤瑾,周庭银,陈险峰,袁轶群,武楠,汤荣,刘庆忠,杨海慧,卫颖珏,张蓓,黄卫春,王金铎,魏丽,胡必杰,黄声雷,李娜,臧先林,张正银,孙晴,沈燕雅,金文敏,孙杰,沈思娣,康向东,戴俊华,唐群力,冯景,汪瑞忠,房华,唐之俭,王芳,张莉,秦云.2011年上海地区细菌耐药性监测[J].中国感染与化疗杂志,2012,12(6):401-411. 被引量:39
  • 6胡付品,朱德妹,汪复,蒋晓飞,杨青,徐英春,张小江,孙自镛,陈中举,王传清,王爱敏,倪语星,孙景勇,俞云松,林洁,单斌,杜艳,徐元宏,沈继录,张泓,孔菁,卓超,苏丹虹,张朝霞,季萍,胡云建,艾效曼,黄文祥,贾蓓,魏莲花,吴玲.2011年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2012,12(5):321-329. 被引量:526
  • 7BernardsAT,HarinckHI,DijkshoornL,etal.PersistentAcinetobacterbaumannii-Lookinsideyourmedicalequipment [J]. Infect Control HospEpidemiol,2004,25(11):1002-1004.
  • 8ClímacoEC,OliveiraML,Pitondo-SilvaA,etal.Clonalcomplexes104,109and113playingamajorrolein thedissemination ofOXA-carbapenemase-producingAcinetobacterbaumanniiinSoutheastBrazil[J].InfectGenetEvol,2013,19:127-133.
  • 9HuangL, SunL, YanY.ClonalspreadofcarbapenemresistantAcinetobacterbaumanniiST92inaChinesehospitalduringa6-yearperiod[J].JMicrobiol,2013,51(1):113-117.
  • 10GurungM,RhoJS,LeeYC,etal.Emergenceandspread of carbapenem-resistant Acinetobacterbaumanniisequencetype191inaKoreanhospital[J].InfectGenetEvol,2013,19:219-222.

二级参考文献22

  • 1Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J]. N Engl J Med, 2009, 360(5) : 439-443.
  • 2Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Tweenty-first in- formational supplement, 2011, M100-S21 Vol 31 No. 1.
  • 3Falagas ME, Giannopoulou KP, Kokolakis GN, et al. Fosfo- mycin: use beyond urinary tract and gastrointestinal infec tions[J]. Clin Infect Dis, 2008, 46(7): 1069-1077.
  • 4Olsson-Liljequist B, Burman LG. Introducing fosfomycin for surgical prophylaxis-emergence of resistance in aerobic faecal gram-negative bacteria of in patients, but not among strains causing infection after elective colorectal procedures [J ]. Scand J Infect Dis, 1993, 25(6) :725-733.
  • 5Andaker L, Burman LG, Eklund A, et al. Fosfomycin/met- ronidazole compared with doxycycline/metronidazole for the prophylaxis of infection after elective coloreetal surgery: a randomised double blind multicentre trial in 517 patients[J]. Eur J Surg, 1992, 158(3):181 185.
  • 6Nohr M, Andersen JC, Juul-Jensen KE. Prophylactic single dose fosfomycin and metronidazole compared with neomycin, haeitraein, metronidazole and ampicillin in elective colorectal operations[J]. Acta Chir Seand, 1990, 156(3):223-230.
  • 7Lindhagen J, Hadziomerovic A, Nordlung S, et al. Comparison of systemic prophylaxis with metronidazole-fosfomycin and met- ronidazole-cephalothin in elective colorectal surgery[J]. Acta Chir Scand, 1981, 147(4):277-283.
  • 8Clinical and Laboratory Standads Institute. Performance Standards for Antimicrobial Susceptibility Testing[S]. Twenty-First In?formational Supplement v Zul l .M1()O-S21 Vol. 31 No. 1.
  • 9Endimiani A, Patel G. Hujer KM. et al. In vitro activity of fosfomycin against blaKPC-Containing Klebsiella pneumoni?ae isolates, including those nonsusceptible to tigecycline and/ or coiistin] ] ]. Antimicrob Agents Chernother , 201 (), 54( 1) : 526-529.
  • 10Falagas ME, Giannopoulou KP, Kokdakis GN, et al. Fosfo?mycin , use beyond urinary tract and gastrointestinal infec?tions[J]. Clin Infect Dis. 200S, 46(7): 1069-1077.

共引文献567

同被引文献18

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部